tirzepatide and psoriatic arthritis Concomitant ixekizumab significantly improved disease activity and promoted weight reduction versus ixekizumab alone in adults with PsA and obesity or overweight in the TOGETHER-PsA phase 3b trial. Read Results of the phase 3b

Semanext Injection may start reducing appetite and increasing fullness within the first few weeks

For a clinician-facing summary of timing and management considerations see this safety review

But there are some simple ways to approach this side effect if it happens to you

One can maintain an even tan throughout the months with the help of proper skincare and consistency

May lead to faster and greater weight loss compared to Semaglutide

The phenomenon affects 1530% of patients who lose more than 15% of body weight within six months, with risk factors including age over 45, baseline low facial volume, and insufficient protein intake during treatment